Aliases & Classifications for Eating Disorder

Aliases & Descriptions for Eating Disorder:

Name: Eating Disorder 12 14
Eating Disorders 52 41 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8670
ICD10 33 F50 F50.9
ICD9CM 35 307.50
NCIt 47 C89332
UMLS 69 C0013473

Summaries for Eating Disorder

MedlinePlus : 41 eating disorders are serious behavior problems. they can include severe overeating or not consuming enough food to stay healthy. they also involve extreme concern about your shape or weight. types of eating disorders include anorexia nervosa, in which you become too thin, but you don't eat enough because you think you are fat bulimia nervosa, which involves periods of overeating followed by purging, sometimes through self-induced vomiting or using laxatives binge-eating, which is out-of-control eating women are more likely than men to have eating disorders. they usually start in the teenage years and often occur along with depression, anxiety disorders, and substance abuse. eating disorders can lead to heart and kidney problems and even death. getting help early is important. treatment involves monitoring, talk therapy, nutritional counseling, and sometimes medicines. nih: national institute of mental health

MalaCards based summary : Eating Disorder, also known as eating disorders, is related to personality disorder and autism spectrum disorder, and has symptoms including adipsia and symptoms concerning nutrition, metabolism, and development. An important gene associated with Eating Disorder is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are Peptide ligand-binding receptors and Neuroscience. The drugs Ethanol and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A specific developmental disorder that is characterized by abnormal eating habits that may involve either insufficient or excessive food intake to the detriment of an individual's physical and emotional health.

Wikipedia : 71 An eating disorder is a mental disorder defined by abnormal eating habits that negatively affect a... more...

Related Diseases for Eating Disorder

Diseases related to Eating Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 177)
id Related Disease Score Top Affiliating Genes
1 personality disorder 29.2 BDNF CCK CNR1 COMT DRD2 HTR2C
2 autism spectrum disorder 28.9 BDNF CCK CNR1 COMT GHRL POMC
3 body dysmorphic disorder 28.9 ADIPOQ ALB GHRL LEP LEPR MC4R
4 schizophrenia 28.7 BDNF CCK CNR1 COMT DRD2 HTR2C
5 bulimia nervosa 11.8
6 anorexia nervosa 11.4
7 rumination disorder 11.4
8 borderline personality disorder 10.9
9 anorexia nervosa 1 10.7
10 wernicke-korsakoff syndrome 10.7
11 obesity 10.5
12 pica disease 10.5
13 hypothalamic disease 10.5
14 telogen effluvium 10.5
15 brittle diabetes 10.5
16 mbd25-related intellectual disability 10.5
17 cerebral beriberi 10.5
18 korsakoff's amnesic syndrome 10.5
19 obesity, ucp3-related 10.3 GHRL MC4R
20 intrahepatic gall duct cancer 10.2 BDNF COMT SLC6A4
21 chronic eosinophilic pneumonia 10.2 BDNF COMT SLC6A4
22 mandibular cancer 10.2 CCK GHRL SLC6A4
23 kashin-beck disease 10.2 BDNF CNR1 NPY
24 ornithosis 10.2 CCK DRD2 SLC6A4
25 apperceptive agnosia 10.2 COMT DRD2 SLC6A4
26 ischemic neuropathy 10.2 CCK DRD2 GHRL
27 postencephalitic parkinson disease 10.2 BDNF DRD2 SLC6A4
28 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.2 CCK GHRL PYY
29 urea cycle disorder 10.2 BDNF COMT DRD2
30 sweat gland cancer 10.2 CCK PYY SLC6A4
31 intracranial cavernous angioma 10.1 DRD2 SLC6A3 SLC6A4
32 breast reconstruction 10.1 BDNF COMT DRD2
33 splenic abscess 10.1 DRD2 SLC6A3 SLC6A4
34 pyromania 10.1 DRD2 SLC6A3 SLC6A4
35 cleft lip palate-tetraphocomelia 10.1 LEP POMC
36 nephrogenic adenoma of the urethra 10.1 DRD2 SLC6A3 SLC6A4
37 waardenburg's syndrome 10.1 DRD2 HTR2C SLC6A4
38 alopecia 10.1 BDNF CNR1 DRD2 SLC6A4
39 alexithymia 10.1
40 cytomegalic congenital adrenal hypoplasia 10.1 BDNF COMT DRD2 SLC6A4
41 rectosigmoid junction neoplasm 10.1 CNR1 DRD2 SLC6A3
42 interstitial emphysema 10.1 DRD2 HTR2C SLC6A4
43 rhinoscleroma 10.1 COMT DRD2
44 central nervous system leiomyoma 10.1 ALB GHRL LEP
45 multiple personality disorder 10.1 BDNF COMT HTR2C SLC6A4
46 primary angle-closure glaucoma 10.1 BDNF COMT HTR2C SLC6A4
47 fissured tongue 10.1 ALB CCK NPY
48 simultanagnosia 10.1 CCK CNR1 POMC
49 chondroma 10.1 CCK LEP POMC
50 cervical carcinosarcoma 10.1 CCK CNR1 POMC

Graphical network of the top 20 diseases related to Eating Disorder:



Diseases related to Eating Disorder

Symptoms & Phenotypes for Eating Disorder

UMLS symptoms related to Eating Disorder:


adipsia, symptoms concerning nutrition, metabolism, and development

MGI Mouse Phenotypes related to Eating Disorder:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.49 ADIPOQ BDNF CCK CNR1 COMT DRD2
2 homeostasis/metabolism MP:0005376 10.48 LEP LEPR MC4R NPY POMC PYY
3 growth/size/body region MP:0005378 10.37 ADIPOQ BDNF CNR1 DRD2 HTR2C LEP
4 endocrine/exocrine gland MP:0005379 10.35 ADIPOQ ALB BDNF CCK COMT DRD2
5 adipose tissue MP:0005375 10.33 ADIPOQ CNR1 DRD2 GHRL HTR2C LEP
6 nervous system MP:0003631 10.3 NPY POMC PYY BDNF CCK CNR1
7 mortality/aging MP:0010768 10.25 ADIPOQ ALB BDNF CNR1 DRD2 HTR2C
8 integument MP:0010771 10.24 DRD2 HTR2C LEP LEPR POMC SLC6A3
9 digestive/alimentary MP:0005381 10.18 ALB BDNF CNR1 DRD2 GHRL LEP
10 normal MP:0002873 10.14 ALB BDNF CNR1 DRD2 GHRL LEPR
11 liver/biliary system MP:0005370 10.13 ADIPOQ ALB DRD2 LEP LEPR MC4R
12 muscle MP:0005369 10.1 SLC6A3 SLC6A4 ADIPOQ ALB DRD2 HTR2C
13 neoplasm MP:0002006 10.02 ADIPOQ ALB DRD2 LEP LEPR MC4R
14 no phenotypic analysis MP:0003012 9.98 BDNF CCK CNR1 DRD2 LEPR MC4R
15 renal/urinary system MP:0005367 9.92 ADIPOQ ALB COMT DRD2 LEP LEPR
16 reproductive system MP:0005389 9.86 BDNF CNR1 COMT DRD2 LEP LEPR
17 respiratory system MP:0005388 9.7 ADIPOQ BDNF DRD2 LEP LEPR MC4R
18 skeleton MP:0005390 9.61 ADIPOQ CNR1 DRD2 LEP LEPR MC4R
19 obsolete other MP:0005395 9.54 ADIPOQ CNR1 LEPR
20 taste/olfaction MP:0005394 8.92 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Eating Disorder

Drugs for Eating Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 862)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
2
Norepinephrine Approved Phase 4,Phase 1 51-41-2 439260
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
4
Zinc Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
5
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
6
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
7
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
8
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2 83150-76-9 383414 6400441
9
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 50-23-7 5754 657311
10
Olanzapine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 132539-06-1 4585
11
Topiramate Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 97240-79-4 5284627
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
13
Metyrapone Approved Phase 4 54-36-4 4174
14
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
15
Benzocaine Approved Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
16
Ropivacaine Approved Phase 4,Phase 2 84057-95-4 71273 175805
17
Pimecrolimus Approved, Investigational Phase 4,Phase 2 137071-32-0 6447131 17753757
18
Insulin Aspart Approved Phase 4,Phase 2 116094-23-6 16132418
19
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
20
Insulin-glulisine Approved Phase 4,Phase 2 207748-29-6
21
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
22
Lumefantrine Approved Phase 4 82186-77-4 6437380
23
Artemether Approved Phase 4 71963-77-4 119380 68911
24
Insulin Lispro Approved Phase 4,Phase 2,Phase 1 133107-64-9
25 Zinc sulfate Approved Phase 4 7733-02-0
26
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
27
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
28
Baclofen Approved Phase 4 1134-47-0 2284
29
Pioglitazone Approved, Investigational Phase 4,Phase 2 111025-46-8 4829
30
Testosterone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 58-22-0 6013
31
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
32
Cisplatin Approved Phase 4,Phase 3,Phase 2 15663-27-1 84093 441203 2767
33
Iron Approved Phase 4,Phase 2,Phase 3,Phase 1 7439-89-6 23925
34
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
35
Mycophenolic acid Approved Phase 4,Phase 1 24280-93-1 446541
36
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 1 128794-94-5 5281078
37
Lisinopril Approved, Investigational Phase 4 83915-83-7 5362119
38
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
39
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
40
Memantine Approved, Investigational Phase 4 19982-08-2 4054
41
Histamine Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
42
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
43
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
44
Clozapine Approved Phase 4 5786-21-0 2818
45
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
46
Cyproheptadine Approved Phase 4 129-03-3 2913
47
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2 113-45-1 4158
48
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2 76631-46-4, 113775-47-6 68602 5311068 56032
49
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
50
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386

Interventional clinical trials:

(show top 50) (show all 2676)
id Name Status NCT ID Phase
1 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
2 Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel Unknown status NCT01142440 Phase 4
3 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4
4 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
5 Organization Program of DiabEtes INsulIN ManaGement Unknown status NCT01338376 Phase 4
6 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
7 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
8 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4
9 Diabetes Prevention Program in Schizophrenia [DPPS] Unknown status NCT00182494 Phase 4
10 The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer Unknown status NCT01845922 Phase 4
11 Comparing Long-acting Insulins During Exercise in Type 1 Diabetes Unknown status NCT01440439 Phase 4
12 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4
13 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
14 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
15 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
16 Transversus Abdominis Plane Blocks With Abdominoplasty Unknown status NCT01278264 Phase 4
17 An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder Completed NCT00330655 Phase 4
18 Folic Acid Supplementation in Eating Disorder Completed NCT01493674 Phase 4
19 Effectiveness of Binge Eating Disorder Treatments Completed NCT00060762 Phase 4
20 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4
21 Atomoxetine in the Treatment of Binge Eating Disorder Completed NCT00327834 Phase 4
22 Study of Duloxetine vs Placebo in Treatment of Binge Eating Disorder With Depression Completed NCT00607789 Phase 4
23 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4
24 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4
25 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4
26 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4
27 Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm Completed NCT02060084 Phase 4
28 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4
29 Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese Completed NCT01739049 Phase 4
30 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4
31 The Effects of Body Contouring: Abdominoplasty and Liposuction Completed NCT02151799 Phase 4
32 Baclofen for Rumination Completed NCT03113396 Phase 4
33 Treatment of Binge Eating in Obese Patients in Primary Care Completed NCT00537810 Phase 4
34 Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons Completed NCT00516919 Phase 4
35 Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults Completed NCT02706067 Phase 4
36 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4
37 Physical and Chemical Study of Atherosclerosis Mechanisms Completed NCT01700075 Phase 4
38 The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents Completed NCT02365025 Phase 4
39 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4
40 Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia Completed NCT00981526 Phase 4
41 Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment Completed NCT00651183 Phase 4
42 Energy Homeostasis Under Treatment With Atypical Antipsychotics Completed NCT00148564 Phase 4
43 Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Completed NCT00485823 Phase 4
44 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4
45 Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation Completed NCT01036841 Phase 4
46 A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants Completed NCT01804244 Phase 4
47 The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet Completed NCT00138645 Phase 4
48 Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder Completed NCT00190749 Phase 4
49 Flavonoid Supplementation and Endothelial Function Completed NCT00331227 Phase 4
50 Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine Completed NCT00312598 Phase 4

Search NIH Clinical Center for Eating Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Eating Disorder

Anatomical Context for Eating Disorder

MalaCards organs/tissues related to Eating Disorder:

39
Heart, Kidney, Testes, Bone, Brain, Breast, Ovary

Publications for Eating Disorder

Articles related to Eating Disorder:

(show top 50) (show all 928)
id Title Authors Year
1
Treating the binge or the (fat) body? Representations of fatness in a gold standard psychological treatment manual for binge eating disorder. ( 28064539 )
2017
2
Evidence for ERP biomarkers of eating disorder symptoms in women. ( 28057515 )
2017
3
Prevalence and correlates of binge eating disorder related features in the community. ( 27899295 )
2017
4
Psychiatric comorbidity and maternal distress among adolescent eating disorder patients: A comparison with substance use disorder patients. ( 28039823 )
2017
5
Addison's Disease and Possible Cannabis Withdrawal Syndrome Presenting as an Eating Disorder in a Thirty-Year-Old Female. ( 28348901 )
2017
6
Female athlete experiences of seeking and receiving treatment for an eating disorder. ( 28051927 )
2017
7
Rumination in Patients with Binge-Eating Disorder and Obesity: Associations with Eating-Disorder Psychopathology and Weight-bias Internalization. ( 28078784 )
2017
8
Eating Disorder Examination Questionnaire (EDE-Q) and Clinical Impairment Assessment (CIA): clinical norms and functional impairment in male and female adults with eating disorders. ( 28084126 )
2017
9
'I can't accept that feeling': Relationships between interoceptive awareness, mindfulness and eating disorder symptoms in females with, and at-risk of an eating disorder. ( 27915166 )
2017
10
Adolescent and young adult women's opinions of common eating disorder prevention messages. ( 28059633 )
2017
11
Attention-deficit/hyperactivity disorder symptoms and psychological comorbidity in eating disorder patients. ( 28534123 )
2017
12
Fifty years of anorexia nervosa and other eating disorders in the Australian & New Zealand Journal of Psychiatry. ( 28521537 )
2017
13
Cue-exposure software for the treatment of bulimia nervosa and binge eating disorder. ( 27776602 )
2016
14
Predicting Dropout from Intensive Outpatient Cognitive Behavioural Therapy for Binge Eating Disorder Using Pre-treatment Characteristics: A Naturalistic Study. ( 27594180 )
2016
15
Mothers and Fathers with Binge Eating Disorder and Their 18-36 Months Old Children: A Longitudinal Study on Parent-Infant Interactions and Offspring's Emotional-Behavioral Profiles. ( 27199815 )
2016
16
Use of yoga in outpatient eating disorder treatment: a pilot study. ( 27980773 )
2016
17
Integrating eating disorder-specific risk factors into the acquired preparedness model of dysregulated eating: A moderated mediation analysis. ( 28033537 )
2016
18
Academic burnout and eating disorder among students in Monash University Malaysia. ( 27131097 )
2016
19
Dimensions of Compulsive Exercise across Eating Disorder Diagnostic Subtypes and the Validation of the Spanish Version of the Compulsive Exercise Test. ( 27933021 )
2016
20
REbeL Peer Education: A model of a voluntary, after-school program for eating disorder prevention. ( 27593168 )
2016
21
Eating disorder symptoms in middle-aged and older men. ( 27173753 )
2016
22
Associations between emotion regulation difficulties, eating disorder symptoms, non-suicidal self-injury, and suicide attempts in a heterogeneous eating disorder sample. ( 27978502 )
2016
23
Life adverse experiences in relation with obesity and binge eating disorder: A systematic review. ( 28092189 )
2016
24
Identification and Evolutionary Analysis of Potential Candidate Genes in a Human Eating Disorder. ( 27088090 )
2016
25
The ABBA study - approach bias modification in bulimia nervosa and binge eating disorder: study protocol for a randomised controlled trial. ( 27670138 )
2016
26
Emotion regulation difficulties in binge eating disorder with and without the overvaluation of weight and shape. ( 27631564 )
2016
27
Medical comorbidity of binge eating disorder. ( 27553016 )
2016
28
Residential cognitive-behavioral weight-loss intervention for obesity with and without binge-eating disorder: A prospective case-control study with five-year follow-up. ( 27203183 )
2016
29
Development and Psychometric Validation of the EDE-QS, a 12 Item Short Form of the Eating Disorder Examination Questionnaire (EDE-Q). ( 27138364 )
2016
30
Evolving eating disorder psychopathology: conceptualising muscularity-oriented disordered eating. ( 27143005 )
2016
31
Binge-eating disorder in the Swedish national registers: Somatic comorbidity. ( 27642179 )
2016
32
Rapid response to eating disorder treatment: A systematic review and meta-analysis. ( 27528478 )
2016
33
Disentangling body image: The relative associations of overvaluation, dissatisfaction, and preoccupation with psychological distress and eating disorder behaviors in male and female adolescents. ( 27539911 )
2016
34
Examining binge-eating disorder and food addiction in adults with overweight and obesity. ( 27558207 )
2016
35
An Unusual Etiology of Hypokalemia in a Patient With an Eating Disorder. ( 28029538 )
2016
36
A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. ( 26942768 )
2016
37
An Interactive, Graphical Tool for Retrospectively Assessing Symptom Frequency and Severity: An Illustration With Eating Disorder Behaviors, Body Weight, and Stress. ( 27637739 )
2016
38
Contribution of Interpersonal Problems to Eating Disorder Psychopathology via Negative Affect in Treatment-seeking Men and Women: Testing the Validity of the Interpersonal Model in an Understudied Population. ( 28028886 )
2016
39
Development and preliminary validation of a Finnish version of the Eating Disorder Examination Questionnaire (EDE-Q). ( 27152496 )
2016
40
Risk factors for eating disorder symptoms at 12 years of age: A 6-year longitudinal cohort study. ( 27612559 )
2016
41
Universal prevention efforts should address eating disorder pathology across the weight spectrum: Implications for screening and intervention on college campuses. ( 27090854 )
2016
42
Association of premenstrual syndrome and premenstrual dysphoric disorder with bulimia nervosa and binge-eating disorder in a nationally representative epidemiological sample. ( 27206163 )
2016
43
Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial. ( 27650406 )
2016
44
Sleep related eating disorder: Importance of prebariatric evaluation-A case report. ( 27614949 )
2016
45
Examining affect and perfectionism in relation to eating disorder symptoms among women with anorexia nervosa. ( 27208513 )
2016
46
Eating disorder severity and functional impairment: moderating effects of illness duration in a clinical sample. ( 27659175 )
2016
47
Massive gastric dilatation: the radiological picture of eating disorder. ( 27041386 )
2016
48
Transitioning from DSM-IV to DSM-5: A systematic review of eating disorder prevalence assessment. ( 27528542 )
2016
49
Advances in Adolescent and Young Adult Eating Disorder Care in Rhode Island. ( 27579944 )
2016
50
A Putative Association of COMT Val(108/158)Met with Impulsivity in Binge Eating Disorder. ( 26621270 )
2016

Variations for Eating Disorder

Expression for Eating Disorder

Search GEO for disease gene expression data for Eating Disorder.

Pathways for Eating Disorder

Pathways related to Eating Disorder according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 CCK CNR1 DRD2 GHRL HTR2C LEP
2 12.27 CNR1 COMT NPY POMC
3
Show member pathways
11.97 BDNF DRD2 GHRL NPY
5
Show member pathways
11.72 BDNF DRD2 SLC6A3
6
Show member pathways
10.97 LEP LEPR POMC
7
Show member pathways
10.86 COMT SLC6A3 SLC6A4
8 10.86 ADIPOQ LEP LEPR NPY POMC
9 10.66 MC4R POMC
10 10.52 CCK CNR1

GO Terms for Eating Disorder

Cellular components related to Eating Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 ADIPOQ ALB CCK GHRL LEP NPY
2 extracellular region GO:0005576 9.65 ADIPOQ ALB BDNF CCK GHRL LEP
3 axon GO:0030424 9.1 CCK CNR1 COMT DRD2 GHRL SLC6A3

Biological processes related to Eating Disorder according to GeneCards Suite gene sharing:

(show all 44)
id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.89 ADIPOQ DRD2 LEP SLC6A4
2 neuropeptide signaling pathway GO:0007218 9.86 NPY POMC PYY
3 response to drug GO:0042493 9.85 ADIPOQ COMT DRD2 HTR2C SLC6A3 SLC6A4
4 locomotory behavior GO:0007626 9.84 DRD2 HTR2C SLC6A3
5 circadian rhythm GO:0007623 9.83 ADIPOQ LEP SLC6A4
6 regulation of blood pressure GO:0008217 9.8 LEP NPY POMC
7 glucose metabolic process GO:0006006 9.8 ADIPOQ GHRL LEP
8 glucose homeostasis GO:0042593 9.76 ADIPOQ CNR1 LEP LEPR
9 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.75 CNR1 DRD2 MC4R
10 response to nicotine GO:0035094 9.73 CNR1 DRD2 SLC6A3
11 response to nutrient GO:0007584 9.73 ADIPOQ CNR1 LEP SLC6A4
12 response to cocaine GO:0042220 9.72 CNR1 DRD2 SLC6A3
13 positive regulation of multicellular organism growth GO:0040018 9.71 DRD2 GHRL SLC6A3
14 response to iron ion GO:0010039 9.69 DRD2 SLC6A3
15 negative regulation of blood pressure GO:0045776 9.69 ADIPOQ CNR1 DRD2
16 neurotransmitter biosynthetic process GO:0042136 9.68 SLC6A3 SLC6A4
17 negative regulation of gluconeogenesis GO:0045721 9.68 ADIPOQ LEPR
18 dopamine metabolic process GO:0042417 9.68 COMT DRD2
19 central nervous system neuron development GO:0021954 9.68 LEP NPY
20 ammonium transmembrane transport GO:0072488 9.67 SLC6A3 SLC6A4
21 prepulse inhibition GO:0060134 9.67 DRD2 SLC6A3
22 regulation of synaptic transmission, GABAergic GO:0032228 9.67 CNR1 DRD2
23 eating behavior GO:0042755 9.67 CCK LEP PYY
24 sexual reproduction GO:0019953 9.65 LEP LEPR
25 behavior GO:0007610 9.65 HTR2C NPY
26 adenohypophysis development GO:0021984 9.65 DRD2 SLC6A3
27 positive regulation of growth hormone secretion GO:0060124 9.64 DRD2 GHRL
28 leptin-mediated signaling pathway GO:0033210 9.64 LEP LEPR
29 monoamine transport GO:0015844 9.63 SLC6A3 SLC6A4
30 dopamine catabolic process GO:0042420 9.62 COMT SLC6A3
31 negative regulation of appetite GO:0032099 9.61 CCK LEP
32 regulation of bone remodeling GO:0046850 9.61 LEP LEPR
33 dopamine uptake involved in synaptic transmission GO:0051583 9.6 SLC6A3 SLC6A4
34 regulation of metabolic process GO:0019222 9.58 LEP MC4R
35 energy reserve metabolic process GO:0006112 9.58 LEP LEPR MC4R
36 positive regulation of appetite GO:0032100 9.57 GHRL NPY
37 response to ethanol GO:0045471 9.55 ADIPOQ CNR1 DRD2 LEP SLC6A3
38 negative regulation of dopamine secretion GO:0033602 9.52 CNR1 DRD2
39 adult feeding behavior GO:0008343 9.5 GHRL LEP NPY
40 bone growth GO:0098868 9.48 LEP LEPR
41 regulation of feeding behavior GO:0060259 9.43 CNR1 LEPR MC4R
42 feeding behavior GO:0007631 9.35 DRD2 HTR2C MC4R NPY PYY
43 regulation of appetite GO:0032098 8.92 HTR2C NPY POMC PYY
44 G-protein coupled receptor signaling pathway GO:0007186 10.17 CNR1 DRD2 GHRL HTR2C MC4R PYY

Molecular functions related to Eating Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.73 ADIPOQ DRD2 LEP NPY POMC SLC6A3
2 neuropeptide hormone activity GO:0005184 9.5 CCK NPY PYY
3 neurotransmitter:sodium symporter activity GO:0005328 9.46 SLC6A3 SLC6A4
4 G-protein coupled receptor binding GO:0001664 9.46 GHRL NPY POMC PYY
5 dopamine binding GO:0035240 9.43 DRD2 SLC6A3
6 monoamine transmembrane transporter activity GO:0008504 9.4 SLC6A3 SLC6A4
7 dopamine:sodium symporter activity GO:0005330 9.37 SLC6A3 SLC6A4
8 drug binding GO:0008144 9.35 ALB CNR1 DRD2 HTR2C SLC6A3
9 hormone activity GO:0005179 9.17 ADIPOQ CCK GHRL LEP NPY POMC

Sources for Eating Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....